By focusing on the interplay among sclerostin, PLR-associated enzymes, and the LCS microenvironment, this study aims to provide new insights into the mechanisms underlying T2DM-related bone quality deterioration and explore potential therapeutic targets for fracture prevention in diabetic patients. The gene discussed is SOST; the disease is type 2 diabetes mellitus.